Callan JMB Inc (CJMB) Stock AnalysisCJMBStock AnalysisCallan JMB Inc

Callan JMB Inc. is a vertically integrated logistics and fulfillment company, which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. The Company provides comprehensive alternatives to all logistics solutions and services utilized for frozen shipping in the life sciences industry (personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). Its Ship2Q ultraviolet disinfection process (Safe Hygienic Irradiation Performance Process & Qualification) ensures fitness, thermal reliability, and cleanliness of the system components within the manufacturers specifications equal to new off-the-shelf shipper systems. It operates in the Industrials sector.

Given the current price of 2.15, the stock's RSI is at 44.57, indicating it is nearing oversold territory but not quite there. The forward P/E ratio is 0, suggesting no earnings expectations, and the gross margin has improved to 55.07% in the latest quarter, but the company continues to report significant net losses, with a net income of -1,231,923 in Q2 2026. The main risk is the substantial year-over-year revenue decline of 12.8%, which raises concerns about the company's operational viability.